Novo Nordisk Earnings & Forecasts

Novo Nordisk (NVO) earnings history, EPS estimates, revenue forecasts and company guidance.

Earnings Per Share (Non-GAAP)

四半期利益の驚きの金額

会計四半期	報告日	実質EPS	推定EPS	驚き％
Q2	Aug 4, 2026	$0.96	$0.81	18.6 %
Q1	May 6, 2026	$1.04	$0.87	19.3 %
Q4	Feb 4, 2026	$1.00	$0.89	12.4 %
Q3	Nov 5, 2025	$1.03	$0.77	33.4 %

Quarterly Revenue (Billions)

四半期売上高の驚きの金額

会計四半期	報告日	実際の収益	推定収益	驚き％
Q2	Aug 4, 2026	$12.21B	$11.35B	7.57 %
Q1	May 6, 2026	$15.17B	$11.13B	36.3 %
Q4	Feb 4, 2026	$12.34B	$12.08B	2.11 %
Q3	Nov 5, 2025	$11.75B	$11.88B	-1.14 %

Novo Nordisk Guidance

Novo Nordisk (NVO) は、5 6, 2026日にfiscal yearの2026に関するガイダンスを直近で発表しました。同社は当期の売上高を$42.39B - $46.24Bの範囲と予想しています。

以前のガイダンスと比較して、Novo Nordiskは売上高予測を以前の範囲である引き上げから$40.46B - $44.32Bに引き上げました。

Novo Nordiskは、15から11 2, 2022の間に5 6, 2026ガイダンスの更新を発表しました。During this period, the company raised its outlook 11 times and lowered it 2 times, providing investors with insight into management's evolving expectations.

Recent Earnings Results

Metric	Q2 '26	Q1 '26	Q4 '25	Q3 '25
Earnings Per Share (Non-GAAP)
Estimate	$0.81	$0.87	$0.89	$0.77
Actual	$0.96	$1.04	$1.00	$1.03
Surprise	+18.6%	+19.3%	+12.4%	+33.4%
Revenue
Estimate	$11.35B	$11.13B	$12.08B	$11.88B
Actual	$12.21B	$15.17B	$12.34B	$11.74B
Surprise	+7.57%	+36.3%	+2.11%	-1.14%

Analyst Estimates — Forward PeriodsSource: Wall Street consensus

Metric	Q3 '26E	Q4 '26E	Q1 '27E	Q2 '27E
Earnings Per Share (Non-GAAP)
Consensus	$0.80	$0.72	$0.91	$0.92
Revenue
Consensus	$11.47B	$12.17B	—	—

More with Benzinga EdgeGet Access

Earnings & Guidance News

Hims & Hers Health: Investments Necessary For Long-Term Incremental Growth, Says Bullish Analyst

HIMS stock edges lower after mixed Q2 results. Needham analyst maintains Buy rating, raises PT to $42. Company's revenue up 38.2% YoY.

Priya Nigam

PRO
Novo Nordisk Q2 Adj. EPS $0.96 Beats $0.81 Estimate, Sales $12.209B Beat $11.350B Estimate

Novo Nordisk (NYSE:NVO) reported quarterly earnings of $0.96 per share which beat the analyst consensus estimate of $0.81 by 18.52 percent. This is a 5.49 percent increase over earnings of $0.91 per share from the same

Benzinga Newsdesk

Ozempic Maker Novo Nordisk Raises Outlook but Sales Fall on Tough Comparison, Stock Tanks

Novo Nordisk raises 2026 guidance as Wegovy pill tops 5 million U.S. prescriptions, but stock falls despite higher GLP-1 sales expectations.

Vandana Singh

PRO
Novo Nordisk Expects Outlook FY Adjusted Revenue Growth -6 To 0%; Q2 Adj Sales Up 7% At CER; Adj Operating Profit Up 11% At CER; Raises 2026 Adj Sales, Operating Profit Outlook To 0% To -6% At Cer; Improved Outlook Is Driven By Increased Expectations For Glp-1 Product Sales

Novo Nordisk today announced adjusted sales and adjusted operating profit for the second quarter of 2026 and raised 2026 full-year adjusted sales and adjusted operating profit outlook at CER.

Benzinga Newsdesk

Earnings Volatility Watch: SanDisk and Nine Other Stocks Could Swing Up To 17.5% This Week

SanDisk, Western Digital and eight other names carry the biggest implied earnings moves in the first week of August, led by the memory chipmakers.

Piero Cingari

Hims & Hers Health Posts Mixed Q1 Amid Weight-Loss Product 'Noise': Analysts

Hims & Hers Health shares tank after disappointing Q1 results. Company raised 2026 revenue outlook. EBITDA outlook was lowered by $25M.

Priya Nigam

Novo Nordisk AS